Rapid Communication

Stronger inhibition of gastric acid secretion by lafutidine, a novel H₂ receptor antagonist, than by the proton pump inhibitor lansoprazole

Hatsushi Yamagishi, Tomoyuki Koike, Shuichi Ohara, Toru Horii, Ryousuke Kikuchi, Shigeyuki Kobayashi, Yasuhiko Abe, Katsunori Iijima, Akira Imatani, Kaori Suzuki, Takanori Hishinuma, Junichi Goto, Tooru Shimosegawa

Abstract

AIM: To compare the antisecretory activity and plasma drug concentrations of a single oral dose of 10 mg lafutidine, a novel H₂ receptor antagonist, with those of the proton pump inhibitor lansoprazole (LPZ) 30 mg.

METHODS: Ten volunteers without H pylori infection participated in this crossover study comparing lafutidine 10 mg with LPZ 30 mg. Intragastric pH was monitored for 6 h in all participants, and blood samples were collected from four randomly selected individuals after single-dose administration of each drug.

RESULTS: The median intragastric pH was significantly higher in individuals who received lafutidine 10 mg than in those who received LPZ 30 mg 2, 3, 4, 5, and 6 h after administration. Maximal plasma drug concentration was reached more promptly with lafutidine 10 mg than with LPZ 30 mg.

CONCLUSION: In H pylori-negative individuals, gastric acid secretion is more markedly inhibited by lafutidine than by LPZ.

© 2008 WJG. All rights reserved.

Key words: Lafutidine; Lansoprazole; H₂ receptor antagonists; Proton pump inhibitors; Antisecretory activity

Peer reviewer: Leonard R Johnson, Professor, Department of Physiology, University Tennessee College of Medicine, 894 Union Ave, Memphis, TN 38163, United States

INTRODUCTION

Gastroesophageal reflux disease (GERD) commonly occurs in the western countries[1,2], and its prevalence is now increasing in Japan[3,4]. Recently, Ohara et al[5] have shown that 42.2% of Japanese adults experience heartburn, similar to the rate of 42.4% reported in western studies[6]. Gastric acid has an important role in the pathogenesis of GERD. Suppression of gastric acid secretion is the most common therapeutic approach, and more effective and promptly acting treatments are required.

Two types of potent gastric acid-suppressing agents, proton pump inhibitors (PPIs) and histamine H₂ receptor antagonists (H₂RAs), are widely used to treat GERD. PPIs such as lansoprazole (LPZ), rabeprazole, and omeprazole, the most potent acid inhibitors available, are often used for first-line treatment. Controlled studies have demonstrated that PPIs are far more effective than H₂RAs in patients with GERD[7-9]. In the treatment of reflux esophagitis, H₂RAs have a number of disadvantages compared to PPIs, including shorter lasting efficacy and the development of tachyphylaxis, both limiting routine use[10]. In contrast, PPIs are highly effective, and produce profound and sustained inhibition of gastric acid secretion, making these agents the mainstay of treatment for GERD.
GERD has a high rate of relapse. The rising use of PPI therapy on demand has raised issues regarding efficacy. Several studies have demonstrated that on demand therapy with PPIs provides an alternative to continuous treatment in patients with non-severe GERD\[11,12\]. However, pH monitoring studies\[13-15\] have shown that PPIs require 2 d to 3 d to inhibit acid secretion efficiently. In contrast, H\(_2\)RAs potently and promptly suppress gastric acid secretion\[16,17\]. In this respect, H\(_2\)RAs might have advantage over PPIs, especially on the first day of treatment, i.e., when used on demand, for GERD. Furthermore, concerning the characteristics of GERD in Japan, it is important to distinguish the significant difference of acid secretion in Japanese patients when compared with that of western countries\[18,19\]. Acid secretion among Japanese patients is lower compared to that of western population irrespective of the status of \(H pylori\) infection. Moreover, endoscopic studies\[14\] have shown that GERD is mild in most Japanese patients. H\(_2\)RAs are thus sometimes used for the treatment of mild-to-moderate GERD in Japan.

Lafutidine is a newly synthesized H\(_2\)RA. Previous studies have shown that lafutidine promptly inhibits gastric acid secretion not only at night but also during the day\[20\], in contrast to other conventional H\(_2\)RAs. Since patients with GERD often have symptoms during the day, we evaluated lafutidine in this study.

Few studies\[21\] have examined the correlation between intragastric pH and blood drug concentrations in the early phase (1-6 h) after a single dose of H\(_2\)RAs or PPIs. The acid inhibitory activity of PPIs depends significantly on cytochrome P450 (CYP) 2C19 genotype, as well as on intrinsic pharmacokinetic and pharmacodynamic characteristics and dosing schemes\[20,21\]. CYP2C19 genotypes were therefore determined for all participants in this study.

The major aim of this study was to compare the antisecretory activity of a single oral dose of 10 mg lafutidine (H\(_2\)RA) with that of a single dose of 30 mg LPZ (PPI). We also examined the correlation between intragastric pH and plasma drug concentrations during the early phase (1-6 h) after single-dose administration.

### MATERIALS AND METHODS

#### Participants

Ten healthy male volunteers aged between 24 years and 48 years (mean, 28.7 years) and weighing 55 kg to 86 kg (mean, 68.6 kg) were included. None of them had a history of gastrointestinal or hepatobiliary disease or of \(H pylori\) eradication therapy. None were receiving regular medication. All volunteers gave written informed consent. The study protocol was approved by the ethical committee of Tohoku University Graduate School of Medicine.

**Detection of \(H pylori\) infection**

\(H pylori\) infection was diagnosed by the \(^{13}\)C-urea breath test\[22\]. A total of 10 \(H pylori\)-negative volunteers were invited and agreed to participate in this study.

**Cytochrome P450 (CYP) 2C19 genotyping**

After obtaining informed consent, a venous blood sample was collected from all participants. DNA was extracted from the nuclei of venous white blood cells. Genetic mutations were analyzed by either the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method\[23\] or by the TaqMan PCR amplification method (Applied Biosystems Japan, Chiba, Japan\[24\]). On the basis of point mutations in exons 4 and 5, CYP2C19 gene status can be classified as homo-extensive metabolizer (homo-EM), hetero-extensive metabolizer (hetero-EM), or poor metabolizer (PM)\[25-27\]. Homo-EM has wild type alleles (wt/wt) without any mutation in exons 5 or 4; PM has mutated alleles (m1/m2) with mutations in both exons 5 and 4 (m1/m2, m1/m1, or m2/m2); and hetero-EM has a mutated allele in either exon 5 or 4 (wt/m1 or wt/m2).

**Study protocol**

All subjects (homo-EM = 3, hetero-EM = 6, PM = 3) participated in an open-label crossover study with lafutidine 10 mg or LPZ 30 mg. They were randomly assigned to receive a single oral dose of lafutidine 10 mg tablets or LPZ 30 mg capsule at a fixed time. A washout period of at least 14 d intervened between the two study periods. Intragastric pH was monitored for 6 h after drug administration. To monitor intragastric pH, a pH electrode was inserted transnasally and positioned fluoroscopically in the gastric corpus, approximately 10 cm below the esophagogastric junction. Intragastric pH was measured at 10-second intervals by means of a portable pH meter attached to a glass pH electrode (Chemical Instrument, Tokyo, Japan). The pH electrode was calibrated before each recording, using standard buffers of pH 1.68, 4.01, and 6.86. The pH data were analyzed using a commercially available software (Chemical Instrument). No food was allowed, and 100 mL of tap water was allowed only when participants felt thirsty. All subjects were instructed to remain upright; normal daily activities were not restricted.

**Sample collection and assay for lafutidine and LPZ plasma concentration**

To study the correlation between intragastric pH and plasma drug concentrations, blood samples were randomly collected from four individuals (No. 3, 5, 6, 7) in heparinized tubes before and 0.25, 0.5, 1, 1.5, 2, 3, 4, and 6 h after drug administration. Blood samples were immediately centrifuged at 3000 r/min for 10 min. All samples were stored at -20 °C until assay. Plasma LPZ levels were measured by high performance liquid chromatography/tandem mass spectrometry\[28,29\]. This method requires only 20 μL of serum and is a simple procedure. Analytes and the internal standard (lanosproazide deuteron derivatives) were separated using a mobile phase of acetonitrile/1 mmol/L ammonium formate (140/60, mL/L) on a C18 analytical column and analyzed in the selected reaction-monitoring (SRM) mode. Detection limit was 500 fg/20 μL.

Plasma lafutidine concentrations were determined by high-performance liquid chromatography (HPLC), using 2-phenyl-1H-benzimidazol as an internal standard (IS). A 1 mL plasma sample added to 0.5 mL of 1 N NaOH and 0.05 mL of IS (20 μg/mL) was mixed with 5 mL of
Our results are attributed to the different mechanisms of action of PPIs and H$_2$RAs. PPIs are absorbed in the small intestine and transported via the systemic circulation to the systemic circulation and then reach gastric cells via the systemic circulation, and then directly and rapidly bind to gastric cell histamine receptors, resulting in immediate inhibition of gastric acid secretion. Inhibition of gastric acid secretion by PPIs is known to significantly depend on CYP2C19 genotype status, as well as on intrinsic pharmacokinetic and pharmacodynamic characteristics and dosing schemes. PPIs, such as LPZ, omeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. As stated above, CYP2C19 genotypes are classified into the three groups: homo-EM, hetero-EM, and PM. Plasma PPI levels and intragastric pH values during PPI treatment are lowest in homo-EM, followed by hetero-EM, and highest in PM. Consequently, some Japanese patients use H$_2$RAs rather than PPIs for the management of mild-to-moderate GERD. Against this background, we compared the H$_2$RA lafutidine with LPZ, one of the most widely used PPIs for the treatment of GERD in Japan.

In this study, lafutidine 10 mg was associated with a significantly prompter rise in intragastric pH and stronger inhibition of gastric acid secretion than was LPZ 30 mg during the early period (1-6 h) after administration of a single oral dose of either drug. Moreover, analysis of blood samples collected from randomly selected subjects showed that lafutidine 10 mg produced a significantly faster prompter rise in the plasma drug concentration than did LPZ 30 mg. These findings suggest that lafutidine 10 mg is especially useful for the on-demand treatment of acid-related symptoms in patients with mild GERD because of its prompter onset of action. However, we must consider the fact that H$_2$RA have a number of disadvantages as compared with PPI, including a shorter duration of action and the development of tachyphylaxis, limiting routine use.

The incidence of atrophic gastritis in the general population is estimated to be higher in Japan than in western countries, whereas gastric acid levels are generally lower in Japan. Moreover, endoscopic studies have reported that most Japanese patients have nonerosive reflux disease or mild forms of GERD. Consequently, some Japanese patients use H$_2$RAs rather than PPIs for the management of mild-to-moderate GERD. Against this background, we compared the H$_2$RA lafutidine with LPZ, one of the most widely used PPIs for the treatment of GERD in Japan.

In this study, lafutidine 10 mg was associated with a significantly prompter rise in intragastric pH and stronger inhibition of gastric acid secretion than was LPZ 30 mg during the early period (1-6 h) after administration of a single oral dose of either drug. Moreover, analysis of blood samples collected from randomly selected subjects showed that lafutidine 10 mg produced a significantly faster prompter rise in the plasma drug concentration than did LPZ 30 mg. These findings suggest that lafutidine 10 mg is especially useful for the on-demand treatment of acid-related symptoms in patients with mild GERD because of its prompter onset of action. However, we must consider the fact that H$_2$RA have a number of disadvantages as compared with PPI, including a shorter duration of action and the development of tachyphylaxis, limiting routine use.

Our results are attributed to the different mechanisms of action of PPIs and H$_2$RAs. PPIs are absorbed in the small intestine and transported via the systemic circulation to the systemic circulation and then reach gastric cells via the systemic circulation, and then directly and rapidly bind to gastric cell histamine receptors, resulting in immediate inhibition of gastric acid secretion. Inhibition of gastric acid secretion by PPIs is known to significantly depend on CYP2C19 genotype status, as well as on intrinsic pharmacokinetic and pharmacodynamic characteristics and dosing schemes. PPIs, such as LPZ, omeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. As stated above, CYP2C19 genotypes are classified into the three groups: homo-EM, hetero-EM, and PM. Plasma PPI levels and intragastric pH values during PPI treatment are lowest in homo-EM, followed by hetero-EM, and highest in PM. Although the subjects this study included 3 PMs, lafutidine 10 mg was associated with a prompter rise in median intragastric pH during the early period (1-6 h) after administration of a single oral dose, as compared with LPZ 30 mg.

**DISCUSSION**

PPIs and H$_2$RAs are potent agents widely used for the treatment of GERD. Recently, the frequency of GERD has been increasing in Japan. Endoscopic studies have shown that the overall prevalence of reflux esophagitis among Japanese adults is 14% to 16%. The increasing use of on-demand PPI therapy has raised various issues regarding efficacy. On-demand therapy has been reported an alternative to continuous treatment in patients with mild-to-moderate GERD who have frequent symptomatic relapses. Although many clinicians regard PPIs to be superior to H$_2$RA in terms of continuous gastric acid suppression, a systematic review of the efficacy of PPIs for heartburn relief during the first 1 d to 2 d of therapy found that symptoms were completely relieved for the entire day in about 30% of patients after their first dose. In contrast, H$_2$RAs potently and quickly suppress gastric acid secretion and may thus have advantages over PPIs, especially for the on-demand treatment of GERD.

The incidence of atrophic gastritis in the general population is estimated to be higher in Japan than in western countries, whereas gastric acid levels are generally lower in Japan. Moreover, endoscopic studies have reported that most Japanese patients have nonerosive reflux disease or mild forms of GERD. Consequently, some Japanese patients use H$_2$RAs rather than PPIs for the management of mild-to-moderate GERD. Against this background, we compared the H$_2$RA lafutidine with LPZ, one of the most widely used PPIs for the treatment of GERD in Japan.

In this study, lafutidine 10 mg was associated with a significantly prompter rise in intragastric pH and stronger inhibition of gastric acid secretion than was LPZ 30 mg during the early period (1-6 h) after administration of a single oral dose of either drug. Moreover, analysis of blood samples collected from randomly selected subjects showed that lafutidine 10 mg produced a significantly faster prompter rise in the plasma drug concentration than did LPZ 30 mg. These findings suggest that lafutidine 10 mg is especially useful for the on-demand treatment of acid-related symptoms in patients with mild GERD because of its prompter onset of action. However, we must consider the fact that H$_2$RA have a number of disadvantages as compared with PPI, including a shorter duration of action and the development of tachyphylaxis, limiting routine use.

Our results are attributed to the different mechanisms of action of PPIs and H$_2$RAs. PPIs are absorbed in the small intestine and transported via the systemic circulation to the systemic circulation and then reach gastric cells via the systemic circulation, and then directly and rapidly bind to gastric cell histamine receptors, resulting in immediate inhibition of gastric acid secretion. Inhibition of gastric acid secretion by PPIs is known to significantly depend on CYP2C19 genotype status, as well as on intrinsic pharmacokinetic and pharmacodynamic characteristics and dosing schemes. PPIs, such as LPZ, omeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. As stated above, CYP2C19 genotypes are classified into the three groups: homo-EM, hetero-EM, and PM. Plasma PPI levels and intragastric pH values during PPI treatment are lowest in homo-EM, followed by hetero-EM, and highest in PM. Although the subjects this study included 3 PMs, lafutidine 10 mg was associated with a prompter rise in median intragastric pH during the early period (1-6 h) after administration of a single oral dose, as compared with LPZ 30 mg.

**DISCUSSION**

PPIs and H$_2$RAs are potent agents widely used for the treatment of GERD. Recently, the frequency of GERD has been increasing in Japan. Endoscopic studies have shown that the overall prevalence of reflux esophagitis among Japanese adults is 14% to 16%. The increasing use of on-demand PPI therapy has raised various issues regarding efficacy. On-demand therapy has been reported an alternative to continuous treatment in patients with mild-to-moderate GERD who have frequent symptomatic relapses. Although many clinicians regard PPIs to be superior to H$_2$RA in terms of continuous gastric acid suppression, a systematic review of the efficacy of PPIs for heartburn relief during the first 1 d to 2 d of therapy found that symptoms were completely relieved for the entire day in about 30% of patients after their first dose. In contrast, H$_2$RAs potently and quickly suppress gastric acid secretion and may thus have advantages over PPIs, especially for the on-demand treatment of GERD.

The incidence of atrophic gastritis in the general population is estimated to be higher in Japan than in western countries, whereas gastric acid levels are generally lower in Japan. Moreover, endoscopic studies have reported that most Japanese patients have nonerosive reflux disease or mild forms of GERD. Consequently, some Japanese patients use H$_2$RAs rather than PPIs for the management of mild-to-moderate GERD. Against this background, we compared the H$_2$RA lafutidine with LPZ, one of the most widely used PPIs for the treatment of GERD in Japan.

In this study, lafutidine 10 mg was associated with a significantly prompter rise in intragastric pH and stronger inhibition of gastric acid secretion than was LPZ 30 mg during the early period (1-6 h) after administration of a single oral dose of either drug. Moreover, analysis of blood samples collected from randomly selected subjects showed that lafutidine 10 mg produced a significantly faster prompter rise in the plasma drug concentration than did LPZ 30 mg. These findings suggest that lafutidine 10 mg is especially useful for the on-demand treatment of acid-related symptoms in patients with mild GERD because of its prompter onset of action. However, we must consider the fact that H$_2$RA have a number of disadvantages as compared with PPI, including a shorter duration of action and the development of tachyphylaxis, limiting routine use.

Our results are attributed to the different mechanisms of action of PPIs and H$_2$RAs. PPIs are absorbed in the small intestine and transported via the systemic circulation to the systemic circulation and then reach gastric cells via the systemic circulation, and then directly and rapidly bind to gastric cell histamine receptors, resulting in immediate inhibition of gastric acid secretion. Inhibition of gastric acid secretion by PPIs is known to significantly depend on CYP2C19 genotype status, as well as on intrinsic pharmacokinetic and pharmacodynamic characteristics and dosing schemes. PPIs, such as LPZ, omeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. As stated above, CYP2C19 genotypes are classified into the three groups: homo-EM, hetero-EM, and PM. Plasma PPI levels and intragastric pH values during PPI treatment are lowest in homo-EM, followed by hetero-EM, and highest in PM. Although the subjects this study included 3 PMs, lafutidine 10 mg was associated with a prompter rise in median intragastric pH during the early period (1-6 h) after administration of a single oral dose, as compared with LPZ 30 mg.
In conclusion, lafutidine 10 mg has a prompter onset of action than LPZ 30 mg in the early phase (1-6 h) after administration of a single oral dose. Lafutidine may thus offer advantages over LPZ for the on-demand treatment of GERD.

**COMMENTS**

**Background**
The prevalence of gastroesophageal reflux disease (GERD) symptoms is now increasing in Japan. Concerning the characteristics of GERD in Japan, it is important to distinguish the significant difference of acid secretion in Japanese patients when compared with that of patients from western countries. Acid secretion among the Japanese individuals lower when compared to that of the western population irrespectively of H. pylori infection status. In Japan, histamine H₂ receptor antagonists (H₂-RAs) are thus sometimes used for the treatment of mild-to-moderate GERD.

**Research frontiers**
To compare lafutidine 10 mg (H₂-RAs) to LPZ 30 mg (proton pump inhibitors: PPI) in the antisecretory activity and blood drug concentration in the immediate early period after administration of a single dose.

**Innovations and breakthroughs**
Few studies have reported the effect at the early post-administration phase (1-6 h) of single dose of H₂RA and PPI.

**Applications**
We clearly state that lafutidine 10 mg has a prompter onset of action than LPZ 30 mg in the early phase (1-6 h) after administration of a single oral dose. It is reported that rapid acid suppression is important for effective pain relief at the onset of treatment in GERD patients. Therefore, our results show that lafutidine offers advantages over LPZ for the on-demand treatment of GERD.

**Peer review**
This is a nice clear study. The authors ascertained the effectiveness of lafutidine compared with LPZ in the elevation of intragastric pH in the immediate early period after a single oral administration.

**REFERENCES**

1. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. *Gastroenterology* 1997; 112: 1448-1456

2. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). *Scand J Gastroenterol* Suppl 1999; 231: 20-28

3. Ohara S, Kouzu T, Kawano T, Kusano M. [Nationwide epidemiological survey regarding heartburn and reflux esophagitis in Japanese]. *Nippon Shokakibyo Gakkai Zasshi* 2005; 102: 1010-1024

4. Fujimoto K, Iwakiri R, Okamoto K, Oda K, Tanaka A, Tsunoda S, Sakata H, Kikikawa A, Shimoda R, Matsuura K, Watanabe K, Wu B, Nakahara S, Ootani H, Ootani A. Characteristics of gastroesophageal reflux disease in Japan: increased prevalence in elderly women. *J Gastroenterol* 2003; 38 Suppl 15: 3-6
